These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 12975380)

  • 21. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
    Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta.
    Takayanagi H; Kim S; Matsuo K; Suzuki H; Suzuki T; Sato K; Yokochi T; Oda H; Nakamura K; Ida N; Wagner EF; Taniguchi T
    Nature; 2002 Apr; 416(6882):744-9. PubMed ID: 11961557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.
    Ikeda F; Nishimura R; Matsubara T; Tanaka S; Inoue J; Reddy SV; Hata K; Yamashita K; Hiraga T; Watanabe T; Kukita T; Yoshioka K; Rao A; Yoneda T
    J Clin Invest; 2004 Aug; 114(4):475-84. PubMed ID: 15314684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.
    Bharti AC; Takada Y; Aggarwal BB
    J Immunol; 2004 May; 172(10):5940-7. PubMed ID: 15128775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
    Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
    Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast.
    Bai XC; Lu D; Liu AL; Zhang ZM; Li XM; Zou ZP; Zeng WS; Cheng BL; Luo SQ
    J Biol Chem; 2005 Apr; 280(17):17497-506. PubMed ID: 15731115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RANKL-RANK signaling in osteoclastogenesis and bone disease.
    Wada T; Nakashima T; Hiroshi N; Penninger JM
    Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RANK ligand and interferon gamma differentially regulate cathepsin gene expression in pre-osteoclastic cells.
    Pang M; Martinez AF; Jacobs J; Balkan W; Troen BR
    Biochem Biophys Res Commun; 2005 Mar; 328(3):756-63. PubMed ID: 15694411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis.
    Park H; Jung YK; Park OJ; Lee YJ; Choi JY; Choi Y
    J Immunol; 2005 Dec; 175(11):7193-201. PubMed ID: 16301623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis.
    Clohisy JC; Frazier E; Hirayama T; Abu-Amer Y
    J Orthop Res; 2003 Mar; 21(2):202-12. PubMed ID: 12568950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prospects of treatment using interferon for bone diseases].
    Iba K; Takada J; Yamashita T
    Nihon Rinsho; 2006 Jul; 64(7):1275-80. PubMed ID: 16838644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
    Koyama H; Nakade O; Takada Y; Kaku T; Lau KH
    J Bone Miner Res; 2002 Jul; 17(7):1219-29. PubMed ID: 12096835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P; Persson E; Conaway HH; Lerner UH
    J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
    Nagata N; Kitaura H; Yoshida N; Nakayama K
    Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis.
    Li P; Schwarz EM; O'Keefe RJ; Ma L; Boyce BF; Xing L
    J Bone Miner Res; 2004 Feb; 19(2):207-13. PubMed ID: 14969390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner.
    Bai S; Kitaura H; Zhao H; Chen J; Müller JM; Schüle R; Darnay B; Novack DV; Ross FP; Teitelbaum SL
    J Clin Invest; 2005 Oct; 115(10):2742-51. PubMed ID: 16184196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-IFN-γ Antibody Promotes Osteoclastogenesis in Human Bone Marrow Monocyte-Derived Macrophages Co-Cultured with Tuberculosis-Activated Th1 Cells.
    Deng J; Sun D; Luo F; Zhang Q; Chen F; Xu J; Zhang Z
    Cell Physiol Biochem; 2018; 49(4):1512-1522. PubMed ID: 30205409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.